GlassScriptPhysician profile
Mollie K Wolfe
NPI 1598454712
$9,940.86
in general payments reported to CMS, 2019-2025
46 companies · $3,968 in 2025
The $3,968 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,487 · 2024: $3,486 · 2025: $3,968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,697 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,696.89 |
| Education | $243.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,738.11 | 2023-2025 | |
| Lundbeck LLC | $972.69 | 2023-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $642.19 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $598.55 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $500.94 | 2023-2025 | Rexulti, Nuedexta |
| Argenx US, INC. | $480.62 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $429.42 | 2023-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Ucb, INC. | $423.50 | 2023-2025 | Nayzilam, Briviact, Rystiggo |
| Emd Serono, INC. | $363.91 | 2023-2025 | Mavenclad |
| Pfizer INC. | $361.11 | 2023-2025 | |
| Lilly USA, LLC | $346.97 | 2023-2025 | Amyvid, Kisunla, Emgality |
| Eisai INC. | $321.24 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $255.28 | 2024-2025 | Hyqvia |
| Kyowa Kirin, INC. | $247.71 | 2023-2025 | Nourianz |
| Tg Therapeutics, INC. | $209.91 | 2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $203.86 | 2024-2025 | Gocovri |
| Acadia Pharmaceuticals INC | $183.98 | 2023-2025 | Nuplazid |
| Genzyme Corporation | $147.41 | 2023 | |
| Csl Behring | $141.38 | 2024-2025 | Hizentra |
| Axsome Therapeutics, INC. | $140.70 | 2025 | Auvelity, Symbravo |
| Genentech USA, INC. | $129.12 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Neurelis, INC. | $111.93 | 2023-2025 | Valtoco |
| Vanda Pharmaceuticals INC. | $105.91 | 2024-2025 | Ponvory |
| Neurocrine Biosciences, INC. | $98.19 | 2023-2025 | Ongentys, Ingrezza |
| Impel Pharmaceuticals LLC | $92.35 | 2025 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $87.41 | 2023-2025 | Ultomiris, Soliris |
| Revance Therapeutics, INC. | $71.89 | 2024 | Daxxify |
| Amgen INC. | $69.74 | 2024-2025 | Uplizna, Aimovig |
| Microtransponder, INC. | $48.15 | 2025 | |
| Biogen, INC. | $44.73 | 2025 | Skyclarys |
| Janssen Pharmaceuticals, INC | $40.84 | 2024-2025 | Spravato |
| Globus Medical, INC. | $34.78 | 2025 | Senza |
| Impel Pharmaceuticals INC. | $33.96 | 2023 | Trudhesa |
| Merz Pharmaceuticals, LLC | $31.58 | 2025 | Xeomin |
| C2n Diagnostics, LLC | $28.95 | 2025 | Precivityad2 |
| Supernus Pharmaceuticals, INC. | $24.99 | 2025 | |
| Amneal Pharmaceuticals LLC | $22.42 | 2024 | Ongentys |
| Mallinckrodt Hospital Products INC. | $20.30 | 2023 | Acthar |
| Octapharma USA, INC. | $19.28 | 2024 | Panzyga |
| Azurity Pharmaceuticals, INC. | $18.43 | 2024 | Horizant |
| Tanabe Pharma America, INC. | $17.80 | 2024 | |
| Aucta Pharmaceuticals, INC. | $17.30 | 2025 | Motpoly Xr |
| Mylan Specialty L.P. | $16.30 | 2023 | Glatiramer Acetate |
| Insightec,INC | $15.30 | 2025 | Exablate |
| Livanova USA, INC. | $14.89 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Grifols USA, LLC | $14.84 | 2024 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mollie Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.